New eyedrop shows promise for pink eye in small trial
NCT ID NCT05356793
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested a new anti-infective eyedrop called SCH1 in 30 adults with acute infectious conjunctivitis (pink eye). Participants received either the active eyedrop or a placebo. The goal was to see if the drug could completely clear redness and discharge. The trial is complete, and results are being analyzed.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- SCH-1 eyedrop (novel anti-infective)
- What this could lead to
- If successful, this could provide a new treatment option for pink eye, potentially reducing symptoms faster than current care.
- What could go wrong
- This is a small, early-phase trial with only 30 participants. The results may not apply to everyone, and the drug may not prove more effective than a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
30 people
The number who actually took part.
- Started
-
Mar 2021
- Finished
-
Mar 2022
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Conjunctivitis (as defined below) within 72 hours of initial ocular symptoms. * At least 18 years of age. * Subjects capable of understanding the purpose and risks of the study, and able to give informed consent. * Conjunctivitis diagnosis defined as presence of the two cardinal signs of acute conjunctivitis- 1) bulbar conjunctival injection and 2) conjunctival discharge/exudates. * A three-point rating scale (0=absent, 1=mild, 2=moderate, 3=severe) will be employed to grade conjunctival discharge/exudates. * All patients will require a rating of 1(mild) or greater for conjunctival discharge/exudates. * Patients will require a rating of 1 (mild) for bulbar conjunctival injection. Exclusion Criteria: * Conjunctivitis greater than 72 hours after initial ocular symptoms * Corneal ulcer, endophthalmitis, or any other confounding infection of the eye * Patients taking topical anti-inflammatory medications on a chronic basis * Known steroid glaucoma responders * Active herpes ocular infection * Pregnant women * Known allergy to chlorhexidine
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute infectious conjunctivitis (disorder) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jacqueline Dauhajre, MD
Jackson Heights, New York, 11372, United States